MARS 2 is the world's only multicentre randomised clinical trial to evaluate the feasibility of recruiting into a trial of surgery for malignant pleural mesothelioma.
2016 has certainly been an exciting year for the trial as we achieved both feasibility endpoints which is the ability to randomise 25 patients in any 6 months or 50 patients within 24 months. As of the 5 December 2016 (during the World Conference of Lung Cancer) the 50th participant was randomised 5 months ahead of schedule allowing us to declare the trial "feasible"!